🇺🇸 Glibenclamide + Metformin in United States

129 US adverse-event reports

Safety signals — FAERS

Adverse reaction reports describe suspected side effects. A report does not mean the drug caused the event — co-medications, underlying disease and coincidence all contribute.

Most-reported reactions

  1. Blood Glucose Increased — 31 reports (24.03%)
  2. Nausea — 17 reports (13.18%)
  3. Hypoglycaemia — 12 reports (9.3%)
  4. Blood Glucose Decreased — 11 reports (8.53%)
  5. Drug Ineffective — 11 reports (8.53%)
  6. Weight Decreased — 11 reports (8.53%)
  7. Asthenia — 9 reports (6.98%)
  8. Decreased Appetite — 9 reports (6.98%)
  9. Dyspnoea — 9 reports (6.98%)
  10. Vomiting — 9 reports (6.98%)

Source database →

Other Diabetes approved in United States

Frequently asked questions

Is Glibenclamide + Metformin approved in United States?

Glibenclamide + Metformin does not currently have US marketing authorisation in our dataset.

Who is the marketing authorisation holder for Glibenclamide + Metformin in United States?

University of Zambia is the originator. The local marketing authorisation holder may differ — check the official source linked above.